Literature DB >> 32145376

Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease.

Joana B Pereira1, Sara Hall2, Mattis Jalakas3, Michel J Grothe4, Olof Strandberg3, Erik Stomrud3, Eric Westman5, Danielle van Westen2, Oskar Hansson6.   

Abstract

OBJECTIVES: Cholinergic dysfunction plays a prominent role in cognitive impairment in Parkinson's disease (PD). The aim of this study was to assess the relationship of baseline and longitudinal basal forebrain atrophy with cognitive decline and dementia in PD.
METHODS: We included 106 non-demented PD patients, 19 PD dementia (PDD) patients and 42 controls with longitudinal structural MRI and cognitive testing. After 4.2 ± 1.8 years, 20 non-demented PD patients were diagnosed with dementia (PD-dementia converters), whereas the rest of PD patients remained non-demented (stable-PD). We compared MRI volumes of the medial septum/diagonal band (Ch1/Ch2) and nucleus basalis of Meynert (Ch4) between groups. Cox regression analyses were applied to test whether Ch1/Ch2 or Ch4 atrophy could predict future dementia and linear mixed models assessed their association with cognitive decline.
RESULTS: Compared to controls, we found reduced Ch4 baseline volumes in PD-dementia converters (p = .003) and those who already had PDD (p < .001) but not in stable-PD. Over time, there was a greater loss in Ch1/Ch2 volumes in PD-dementia converters and PDD compared to the other groups (p = .004). Baseline and longitudinal Ch4 volumes were associated with cognition (p < .002) and longitudinal Ch4 atrophy predicted future dementia (p = .009).
CONCLUSIONS: Atrophy of Ch4 precedes and predicts future dementia in PD and is followed by changes in Ch1/Ch2, reflecting a posterior-anterior pattern of basal forebrain atrophy. This pattern could be used to track the spread of cholinergic degeneration and identify patients at risk of developing dementia.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Basal forebrain; Cognitive decline; Dementia; Longitudinal MRI; Parkinson's disease

Mesh:

Year:  2020        PMID: 32145376     DOI: 10.1016/j.nbd.2020.104831

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  10 in total

1.  Olfactory function and discrimination ability in the elderly: a pilot study.

Authors:  Sae Uchida; Chiho Shimada; Naoko Sakuma; Fusako Kagitani; Akiko Kan; Shuichi Awata
Journal:  J Physiol Sci       Date:  2022-04-01       Impact factor: 2.781

Review 2.  Morphological basis of Parkinson disease-associated cognitive impairment: an update.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2022-06-20       Impact factor: 3.850

Review 3.  Basal Forebrain Impairment: Understanding the Mnemonic Function of the Septal Region Translates in Therapeutic Advances.

Authors:  Marian Tsanov
Journal:  Front Neural Circuits       Date:  2022-05-31       Impact factor: 3.342

Review 4.  Targeting the M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Louis Dwomoh; Gonzalo S Tejeda; Andrew B Tobin
Journal:  Neuronal Signal       Date:  2022-04-21

Review 5.  Parkinson disease-associated cognitive impairment.

Authors:  Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub
Journal:  Nat Rev Dis Primers       Date:  2021-07-01       Impact factor: 52.329

6.  New Developments in Cholinergic Imaging in Alzheimer and Lewy Body Disorders.

Authors:  Chesney E Craig; Nicola J Ray; Martijn L T M Müller; Nicolaas I Bohnen
Journal:  Curr Behav Neurosci Rep       Date:  2020-10-09

7.  Combined subthalamic and nucleus basalis of Meynert deep brain stimulation for Parkinson's disease with dementia (DEMPARK-DBS): protocol of a randomized, sham-controlled trial.

Authors:  Christine Daniels; Frank Steigerwald; Philipp Capetian; Cordula Matthies; Uwe Malzahn; Peter U Heuschmann; Jens Volkmann
Journal:  Neurol Res Pract       Date:  2020-10-19

8.  Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson's Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy.

Authors:  Sophia Rogozinski; Martin Klietz; Gesine Respondek; Wolfgang H Oertel; Michel J Grothe; Joana B Pereira; Günter U Höglinger
Journal:  Front Aging Neurosci       Date:  2022-04-01       Impact factor: 5.702

9.  Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.

Authors:  Nicola J Ray; Lynn Rochester; Joanna Wilson; Alison J Yarnall; Chesney E Craig; Brook Galna; Sue Lord; Rosie Morris; Rachael A Lawson; Lisa Alcock; Gordon W Duncan; Tien K Khoo; John T O'Brien; David J Burn; John-Paul Taylor
Journal:  Mov Disord       Date:  2020-12-31       Impact factor: 10.338

10.  Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson's disease.

Authors:  Kevin B Wilkins; Jordan E Parker; Helen M Bronte-Stewart
Journal:  Neurobiol Dis       Date:  2020-10-10       Impact factor: 5.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.